Paragon Care stock barely flinched into the FY26 result, closing at A$0.135 after flat short term returns and a weak 90 day run. The headline story is not the share price. It is the split between a solid underlying profit picture and a statutory loss driven by the Infinity provisioning hit. Underlying net profit after tax of A$26m sits in sharp contrast to a statutory net loss of A$16m, which keeps the investment debate firmly on balance sheet strain and how much flexibility the company really has from here.
Is Paragon Care a genuine bargain on a low 0.1x P/S, or is the widening loss profile a warning that the market is pricing in more pain? Compare that gap directly in the valuation analysis for Paragon Care
FY 2026 Earnings Summary
- Revenue (FY 2026 vs FY 2025): A$3.68b vs A$3.61b (reported growth of about 1.8% on an underlying organic basis and 6.7% after management normalisations for Infinity, Ramsay exit and FX)
- Net Income or Loss (FY 2026 vs FY 2025): Underlying NPAT A$26.0m vs earnings from continuing operations of A$20.6m. Statutory net loss of A$16.0m for FY 2026, mainly linked to the Infinity provision
- Basic EPS (FY 2026 vs FY 2025): Trailing twelve month basic EPS of a loss of A$0.0097 vs earnings of A$0.0124 in the prior trailing period. Half year 2 FY 2026 basic EPS of A$0.00318 vs A$0.00444 in half year 2 FY 2025
- EBITDA (FY 2026 vs FY 2025): Underlying EBITDA of A$97.2m vs statutory EBITDA of A$50.8m in FY 2026, showing a large gap between core trading performance and reported results after provisions and adjustments
Prefer clean charts instead of another wall of dense earnings text? See Paragon Care’s full visual breakdown, including its balance sheet strength and funding flexibility, in the latest company report for Paragon Care.
Paragon Care’s Bull Story Hinges On Execution Milestones
The bullish view on Paragon Care hinges on a cleaner, higher margin healthcare platform driven by Asia MedTech growth, GLP drug demand and contract logistics scale. The FY26 numbers show parts of that script playing out. Medical technology delivered double digit growth, with Asia described as very strong and Thailand aesthetics contributing despite early stage margin dilution. That aligns with the claim that Asia MedTech can become a more meaningful earnings driver.
On the logistics side, the new Brisbane distribution centre is fully operational and offsite storage and express transfers remain elevated for now. Management expects those costs to ease as the site is utilised. Contract logistics delivered strong revenue and margin growth with a healthy pipeline, and the multiyear Owens & Minor and QuidelOrtho contracts are in place. These are tangible milestones that support the idea of a more scalable, integrated platform, even while statutory results are weighed down by Infinity.
Reveal whether this operational progress at Paragon Care lines up with institutional expectations and recent price action, and see how analysts are framing the risk and reward skew at A$0.135 with the consensus price target analysis for Paragon Care.Paragon Care Bear Case Focuses On Balance Sheet Strain
The bearish story on Paragon Care is that Infinity, leverage and heavy integration spend will choke balance sheet flexibility and delay any real earnings quality. The FY26 print gives that argument some backing. A statutory net loss of A$16m, despite A$26m of underlying NPAT and A$97.2m of underlying EBITDA, shows how reliant the story still is on adjustments. The Infinity provision sits at A$38m after a A$9.2m write back, so recovery risk is far from closed out.
Bears also worry that integration and the Willawong and Brisbane distribution build keep costs sticky. Management confirms capex has just peaked and offsite storage and express transfers remain elevated. Net debt is around 2.5x EBITDA, and the decision to withhold a dividend while talking about a potential buyback in FY27 supports the view that capital allocation is tight and milestones on clean cash generation are not yet met.
After interest cover concerns, Infinity risk and leverage, are these issues isolated or early signals of deeper structural fragility? Review our risk analysis for Paragon Care which shows 1 important warning sign.Stay Ahead Of Your Next Move
If the split between Paragon Care’s underlying earnings and statutory loss has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the Infinity impact and balance sheet story evolve. When you do hold Paragon Care or other stocks, use the Portfolio Command Center to cut through noise and focus on the most important updates for your positions. For a longer term view, tap into the Community to see how other investors are thinking about similar risks and catalysts. This can help you identify potential turning points and hidden issues early, and stay ahead of the broader market.
Seeking Alternatives Beyond Paragon Care?
Fresh ideas move fast. Breakout themes, early momentum and stocks still flying under the radar for now can get caught by the crowd quickly, so do not delay and act now.
- Spot cash rich compounders before momentum headlines catch up by scanning a curated list of solid balance sheet and fundamentals stocks (22 results) while the best candidates are still quietly priced in.
- Target future facing infrastructure as AI demand builds by reviewing hand picked 55 AI infrastructure stocks that support data centers, chips and high intensity computing capacity.
- Ride potential yield and price stability together by checking carefully filtered 8 dividend fortresses before income focused investors crowd into the same opportunities.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com